Biopharma company Silo Pharma Inc. SILO filed a provisional patent application to the US Patent and Trading Office covering “methods and compositions for pain management” towards ameliorating pain, including chronic pain such as fibromyalgia, with its SP-26 program using a proprietary ketamine composition.
Fibromyalgia is a chronic condition causing pain to the connective tissues including muscles, ligaments and tendons, often associated with sleep difficulties, fatigue, mood disorders, and problems with memory and concentration. It affects nearly 2% of the total U.S. population.
Silo Pharma’s novel drug candidate initially targets this indication, yet the provisional patent application supports the company’s “multi-pronged strategy” for advancing SP-26 into the clinic.
Silo CEO Eric Weisblum is working towards submitting an IND package to the FDA and pursuing the 505(b)(2) regulatory pathway for its drug candidate.
“We believe our drug would serve a critical need in a largely inadequate treatment landscape for chronic pain including fibromyalgia,” he concluded.
See Also: Psychedelic Trials Update - Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder
Furthermore, the Company’s IP and technology rights for the treatment of rare diseases span over six issued and provisional patents, with additional patent applications pending.
Benzinga’s PCC
The second edition of the Benzinga Psychedelics Capital Conference is inching closer each day!
The event will take place at the Fontainebleau Miami Beach Hotel in Florida on April 13, 2023. This is THE place to get DEALS DONE, raise money, jumpstart M&A and meet investors and key partners.
Get your tickets now before prices go up!
Photo by Julia Koblitz on Unsplash
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
